A Randomized, Open Labeled, Placebo Controlled, Two-Arm, Parallel Group, Multi-Centric, Oral Clinical Study To Evaluate The Sns-01/16 In Healthy Adult Human Female Volunteers Under Fasting Conditions.

Start Date28 Feb 2017

Sponsor / Collaborator

Cholayil Pvt Ltd.

NCT01435720

/ Unknown statusPhase 1/2

Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.

Start Date01 Sep 2011

Sponsor / Collaborator

Sevion Therapeutics, Inc.

100 Clinical Results associated with SNS-01

100 Translational Medicine associated with SNS-01

100 Patents (Medical) associated with SNS-01

Literatures (Medical) associated with SNS-01

01 Oct 2014·Nanomedicine (London, England)

siRNA Nanoparticles: The Future of RNAi Therapeutics for Oncology?

Author: Chou, Szu-Ting ; Mixson, A James

siRNA clinical trials: state of the art With the emergence of siRNA-based nanomedicine as a powerful therapeutic strategy for cancers, seven of these therapeutics have now advanced to clinical trials. Carriers of siRNA therapeutics include transferrin-modified cyclodextrin (CALAA-01, Arrowhead Research Corporation, CA, USA), in vivo jetPEI (SNS01-T; Sevion Technologies, NJ, USA), cationic liposomes (ALN-VSP02, Alnylam Pharmaceuticals, MA, USA; TKM080301, Tekmira Pharmaceuticals, Burnaby, Canada; Atu027, Silence Therapeutics, London, UK; and DCRMYC, Dicerna Pharmaceuticals, Watertown, MA, USA) and neutral liposomes (siRNA–EphA2–1,2-dioleoyl-sn-glycero3-phosphocholine [DOPC], MD Anderson Cancer Center, TX, USA ). Among those in clinical trials, the cationic lipoplex targeting MYC1a (DCR-MYC) is the only nanoplex that requires the Dicer enzyme in order to obtain functional siRNA. In 2008, the transferrin-modified cyclodextrin polyplex (CALAA-01) was the first siRNA nanoparticle to be approved for cancer clinical trials. In a preclinical mouse study, a single dose of the cyclodextrin nanoplex targeting luciferase mRNA reduced its activity by 80% [1]. More importantly, melanoma patients receiving CALAA-01 in a Phase I clinical trial showed a 50–80% reduction in the RRM2 mRNA compared with mRNA from untreated tumor tissues [2]. Although this study showed promise, the development of CALAA-01 has been delayed and no results have been reported. SNS01-T is a polyethyleneimine (PEI)based (in vivo JetPEI) nanoparticle containing siRNAs targeting EIF5A and decoy plasmids expressing nonhypusinable eIF5A mutants for treatment of multiple myeloma and non-Hodgkin’s B-cell lymphoma [3]. Francis and colleagues have shown that SNS01-T enhances the antitumor efficacy of lenalidomide and bortezomib in a xenograft model [3]. An open-label, Phase I/II doseescalation study that includes 15 patients is currently underway. Sevion technologies, the manufacturer of SNS01-T, has reported no dose-limiting toxicities in four patients at a dose of 0.2 mg/kg of the nanoparticle. Cationic lipid nanoparticles (LNPs) have effectively downregulated oncogenes in malignant hepatomas (CDH16, PLK1, VEGF and MYC1a) and prostate tumors (PKN3) [4]. While LNPs have a circulation half-life that is longer than 18 h [5], most lipoplexes are ultimately internalized by the liver and spleen. Although the accumulation of lipoplexes may lead to tissue toxicity in these organs at higher dosages, they appear to be well-tolerated by humans at defined dosages. In Phase I clinical trials, the maximum tolerated doses were 0.336, 0.75 and 1.25 mg/kg for Atu027, TKM080301 and ALN-VSP02, respectively. As a result, LNPs targeting PKN3 (Atu027) and PLK1 (TKM080301) have been advanced to Phase II trials. Neutral DOPC liposomes have been used to target ovarian cancers (EPHA2, PTK2, and IL8) and melanoma (thrombin receptor) [6]. While siRNA–EphA2–DOPC inhibited tumor growth by approximately siRNA nanoparticles: the future of RNAi therapeutics for oncology?

01 Sep 2014·Molecular therapy : the journal of the American Society of Gene TherapyQ1 · MEDICINE

SNS01-T Modulation of eIF5A Inhibits B-cell Cancer Progression and Synergizes With Bortezomib and Lenalidomide

Q1 · MEDICINE

Article

Author: Tang, Terence ; Zheng, Qifa ; Liu, Zhongda ; Dondero, Richard ; Francis, Sarah M ; Thompson, John E ; Taylor, Catherine A

The high rates of recurrence and low median survival in many B-cell cancers highlight a need for new targeted therapeutic modalities. In dividing cells, eukaryotic translation initiation factor 5A (eIF5A) is hypusinated and involved in regulation of protein synthesis and proliferation, whereas the non-hypusinated form of eIF5A is a potent inducer of cell death in malignant cells. Here, we demonstrate the potential of modulating eIF5A expression as a novel approach to treating B-cell cancers. SNS01-T is a nonviral polyethylenimine-based nanoparticle, designed to induce apoptosis selectively in B-cell cancers by small interfering RNA-mediated suppression of hypusinated eIF5A and plasmid-based overexpression of a non-hypusinable eIF5A mutant. In this study, we show that SNS01-T is preferentially taken up by malignant B cells, inhibits tumor growth in multiple animal models of B-cell cancers without damaging normal tissues, and synergizes with the current therapies bortezomib and lenalidomide to inhibit tumor progression. The results collectively demonstrate the potential of SNS01-T as a novel therapeutic for treatment of a diverse range of B-cell malignancies.

01 Jan 2014·Molecular therapy. Nucleic acidsQ2 · MEDICINE

From Protein Synthesis to Molecular Biology: The Appealing Tale of eIF-5A

Q2 · MEDICINE

ArticleOA

Author: Caraglia, Michele ; Porcelli, Marina ; Alaia, Concetta

A review.Posttranslational hypusine modification of lysine 50 of the eukaryotic initiation factor 5A (eIF-5A) is associated with the function of this factor in cell proliferation and differentiation and is involved in tumor formation, progression and maintenance (for a review see reference 1).In a Mol. Therapy Issue, Francis et al. report that knock down of hypusine formation in eIF-5A through RNA interference strategies is a promising approach for the treatment of B-cell neoplasia².The authors had previously employed this strategy in models of multiple myeloma to abrogate hypusination of eIF-5A by codelivery of an siRNA targeted to the eIF-5A mRNA along with a plasmid encoding a mutated form of eIF-5a that can be not hypusinated.³ The new twist in the follow-up study is that the authors have demonstrated synergistic activity of this strategy when coupled with well-established modalities of treatment of patients affected by lymphoproliferative diseases, suggesting that this approach could translate readily to a clin. setting.Hypusine modification of eIF-5A is involved in regulation of its activity in both protein synthesis and eukaryotic cell growth.Several strategies have been used to inhibit hypusine formation.N1-guanyl-1,7-diaminoheptane (GC7), a nonspecific inhibitor of one of the two enzymes that mediate the hypusination, efficiently inhibits tumor cell proliferation.However, it gives rise to in vivo toxicity owing to its effect upon other enzymes.^4,5 A way to limit the toxicity of anti-cancer agents is to combine them with other nontoxic drugs that exhibit synergistic inhibition of cell proliferation.In this light, the anticancer cytokine interferon α (IFNα) showed synergistic anticancer activity with GC 7 (reference 6) and IFNα-mediated cell growth inhibition was associated with decreased hypusine synthesis and altered eIF-5A function.⁷ However, eIF-5A is expressed as two different isoforms with different functions: eIF5A1, which in its nonhypusinated form induces mitochondria-mediated apoptosis and eIF5A2, which in its nonhypusinated form loses its oncogenic potential.⁸ Interestingly, GC7 also increases the response of bladder cancer cells to doxorubicin, likely due to its ability to antagonize epithelial-mesenchymal transition through inhibition of eIF-5A2 hypusination and function.⁹ On these bases, the hypusination of both isoforms is essential to the oncogenic activity of eIF-5A and a benefit of the strategy used by Francis et al. is that it completely abrogates hypusine formation in eIF-5A without inducing nonspecific side effects.Lymphoproliferative diseases represent an attractive target for this approach since there is an urgent need for new therapeutic strategies in chemo- or immuno-resistant patients.However, a previous report by Scuoppo et al. revealed a tumor suppressor function for hypusinated eIF5A in lymphoproliferative diseases.¹⁰ These contradictory results were observed in an Eμ-Myc overexpression mouse model of lymphomagenesis that is very similar to Burkitt lymphoma, in which the lack of eIF5A hypusination promotes c-Myc-driven tumorigenesis.This is however the only report of tumor suppressor function of eIF-5A and, therefore merits addnl. investigation.As noted above, the same research group demonstrated the activity of SNS01 in models of multiple myeloma.³ This work advances the strategy reported in the previous report by demonstrating synergistic activity with bortezomib and an additive effect when combined with lenalidomide in inhibiting the growth of lymphoproliferative diseases.The use of combinatorial strategies in the treatment of cancer is an important challenge that requires determination of the optimal combination of complementary agents and their sequence of administration.The choice of optimal therapeutic strategy also depends upon the detection of predictive markers of response to therapy.In the case of eIF-5A targeted strategies, predictive biomarkers have yet to be determined and relevant animal studies are strongly warranted.Moreover, Francis et al. employed polyethylenimine (PEI)-based nanoparticles to deliver their nucleic acid therapy to the tumor tissues.PEI promotes self-assembly of nanoparticles so as to protect their contents from serum nucleases and is an efficient system for delivery of nucleic acids in vivo and in humans.However, only certain PEIs can be used for in vivo applications: they must exhibit an overall pos. charge that allows them to bind to the neg. charged heparan sulfate proteoglycans on the cell surface.This can induce different side effects, such as liver necrosis, adhesion of aggregated platelets, shock after systemic injection at higher doses and stimulation of immune system and lung inflammation.¹¹ Delivery strategies can be optimized through the use of second-generation nucleic acid-nanocarriers such as stabilized nucleic acid lipid particles (SNALPs).It has been demonstrated that SNALPs are able to efficiently deliver miRNAs in the treatment of lymphoproliferative diseases and multiple myeloma without signs of toxic side effects.^12,13 SNALPs can also allow the functionalization of their surface with macrophage escaping mols. (such as polyethylene glycol), active targeting moieties (such as transferrin) or cell penetrating peptides.It was recently reported that miRNAs can be suitable tools to inhibit cell growth through the interference with eIF-5A.¹⁴ The advantage of miRNAs as a therapeutic derives from their ability to inhibit multiple intracellular targets and to give rise to pleiotropic interfering functions upon multiple pathways involved in tumorigenesis and cancer cell proliferation.In conclusion, the manuscript by Francis et al. opens an appealing scenario in which a factor traditionally involved in protein synthesis machinery regulation becomes a mol. target for in vivo anti-cancer approaches.The latter are based on both the use of RNA interference techniques and nanotechnol.-based delivery strategies.Based on the results from Francis et al., exploratory clin. trials are strongly warranted and the optimization based on the search for both the optimal weapon and delivery strategy and on the finding of predictive biomarkers is still required (for a summary, see Figure 1).

News (Medical) associated with SNS-01

22 Nov 2022

·www.biospace.com

Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it has entered into a Sponsored Research Agreement with Washington University in St. Louis, MO, to support development of SNS-101, a conditionally active VISTA-blocking antibody. Research will be conducted in the laboratory of Robert Schreiber, Ph.D., Professor of Pathology & Immunology and Director of the Center for Human Immunology and Immunotherapy Programs, to evaluate the underlying molecular mechanisms that enable SNS-101 to overcome myeloid cell-driven immunosuppression within the tumor microenvironment. “In addition to a deep expertise in immuno-oncology, Dr. Schreiber and his team bring extensive knowledge of the cancer model system planned for these studies as well as access to molecular characterization tools,” said Edward van der Horst, Ph.D., Senior Vice President, Biologics Discovery & Early Development, at Sensei Bio. “Together, we will leverage these attributes to better understand SNS-101’s ability to modulate the tumor microenvironment and potentially achieve tumor rejection where other checkpoint therapies have failed.” Said Dr. Schreiber, “We’re excited to partner with Sensei Bio to further our understanding of how to safely and effectively inhibit VISTA, a promising but challenging target in immuno-oncology. SNS-101 has the potential to unlock VISTA as a powerful immune checkpoint by exploiting the tumor microenvironment using pH-sensitive properties, delivering powerful anti-tumor activity without the negative effects that have thwarted past efforts.” Sensei continues to advance SNS-101 and remains on track to submit an Investigational New Drug application (IND) for SNS-101 in the first half of 2023. The company recently presented preclinical data for the program at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. Disclosure Dr. Schreiber receives compensation as a member of Sensei Biotherapeutics’ Immuno-Oncology Advisory Board, and this financial relationship has been disclosed to Washington University in St. Louis in accordance with institutional policy. About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit , and follow the company on Twitter @SenseiBio and LinkedIn.

Immunotherapy

04 Oct 2022

·www.globenewswire.com

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival - SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a pH-independent VISTA antibody BOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today presented additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The presentation contains data from an ongoing collaboration with scientists at Washington University, St. Louis, investigating the mechanism of action of SNS-101. “VISTA remains a promising but difficult-to-drug immuno-oncology target due to significant on-target/off-tumor activity. We’re excited to collaborate with Sensei Bio on studies exploring the efficacy and mechanism of action of their conditionally active, pH-dependent VISTA-blocking antibody, SNS-101,” said Robert D. Schreiber, Ph.D., Andrew M. and Jane M. Bursky Distinguished Professor, Pathology & Immunology at the Washington University School of Medicine in St. Louis and a member of Sensei’s Immuno-Oncology Advisory Board. “In our PD-1-resistant, immunocompetent 1956 tumor model, we observed strong synergistic anti-tumor activity of SNS-101 in combination with PD-1 inhibition, resulting in five out of eight complete responses versus only one out of eight in the PD-1 monotherapy control group.” “These preclinical data demonstrate that the selectivity of our conditionally active VISTA-blocking antibody has the potential to avoid poor pharmacokinetics from target-mediated drug disposition and lower the risk of cytokine release syndrome, while significantly enhancing the anti-tumor effects of PD-1 blockade selectively within tumors,” said Edward van der Horst, Ph.D., Senior Vice President, Biologics Discovery & Early Development. “These findings support the scientific rationale for Sensei’s pH-selective approach, which we believe could offer numerous safety and efficacy advantages over pH-independent antibodies targeting VISTA, including the potential to inhibit tumor growth across a range of indications.” Summary of Key Data: SNS-101 potently inhibited the critical pH-dependent interaction between VISTA and PSGL-1, as well as interactions with other putative receptors. In vitro and in vivo cytokine release syndrome (CRS) assays demonstrate that SNS-101 significantly reduced cytokine induction as compared to a pH-independent VISTA antibody, suggesting that SNS-101 has potential to significantly lower the risk of CRS. Pharmacokinetics studies demonstrate that the pH-sensitive binding of SNS-101 avoided the rapid clearance by target-mediated drug disposition (TMDD) that has been observed with pH-independent VISTA antibodies. SNS-101 demonstrated significant enhancement of anti-tumor effects in combination with anti-PD-1 antibodies in multiple syngeneic tumor models. The full poster is available for viewing on Sensei’s corporate website. About Sensei Biotherapeutics Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development of Sensei’s product candidates and platforms, including SNS-101; the potential safety profile of Sensei’s product candidates, including SNS-101; and the potential benefits of SNS-101, including the potential to overcome pharmacokinetic and safety issues associated with targeting the VISTA immune checkpoint, including target-mediated drug disposition and cytokine release syndrome, as well as the potential to enhance anti-tumor effects in combination with anti-PD-1 antibodies and inhibit tumor growth across a range of indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies, including the preclinical studies described in this press release, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2022 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Michael Biega Senior Director, Investor Relations Sensei Biotherapeutics mbiega@senseibio.com Media Contact: Chris Railey Ten Bridge Communications chris@tenbridgecommunications.com

CollaborateAntibodyImmunotherapyAACR

01 Sep 2022

·www.globenewswire.com

Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody

BOSTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today reported preliminary preclinical data from mouse and non-human primate studies of SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation). “These preclinical data demonstrate that our conditionally active, pH-selective antibody successfully overcomes pharmacokinetic issues associated with targeting the VISTA immune checkpoint, including target-mediated drug disposition and cytokine release syndrome, in these models. The data also differentiate SNS-101 from non-selective antibodies by showing expansion of naïve and memory T cell phenotypes in vivo, as well as significant enhancement of anti-tumor effects in combination with anti-PD-1 antibodies as compared to anti-PD-1 antibodies alone,” said Robert Pierce, M.D., Chief R&D Officer. “These results represent important progress for our SNS-101 program and a potential breakthrough for the field of VISTA inhibition as a novel therapeutic approach in multiple solid tumor indications. We are thrilled with these preliminary results and the potential of SNS-101 to provide a new standard of care to patients in need of innovative treatment options.” In a whole-blood assay at neutral pH, a clinical-stage, pH-independent VISTA antibody induced release of pro-inflammatory cytokines, such as IFNy and TNF, at substantially higher levels of concentration compared with Sensei’s pH-selective VISTA antibody SNS-101, across doses ranging from 1 g/mL to 100 g/mL. These preclinical data support the Company’s hypothesis that pH-driven, conditional binding of SNS-101 could be an effective mechanism for preventing the on-target, off-tumor VISTA binding that has been shown to drive cytokine release syndrome in human patients. SNS-101 also displayed a favorable pharmacokinetic profile in non-human primates compared with a clinical-stage, pH-independent VISTA antibody. Whereas the pH-independent antibody exhibited target-mediated drug disposition and clearance from the blood within hours of administration due to interaction with VISTA-positive immune cells, the SNS-101 concentration declined linearly with a median half-life of approximately three weeks. These data strongly support the Company’s belief that SNS-101’s selective binding to VISTA at low pH, like that found in the tumor microenvironment, has potential to mitigate the pharmacokinetic and safety issues associated with off-tumor binding and unregulated activity. Finally, experiments in a mouse tumor model demonstrated a significant increase in the production of anti-tumor CD8+ T cells among animals treated with a combination of SNS-101 and anti-PD-1 antibodies compared with PD-1 alone, which correlated with tumor growth inhibition. Because CD8+ T cells are essential tumor-destroying immune cells, these data provide encouraging evidence that this therapeutic combination has potential to generate a highly effective anti-tumor response in patients. IND-enabling studies are underway to evaluate the potential of SNS-101 as a novel treatment for solid cancers, both as a monotherapy and in combination with the blockade of other immune checkpoints. The Company plans to file an IND during the first half of 2023. Additional information from these studies can be found in the Company’s corporate presentation, available on the Company’s website, and in its SEC filings. More detailed findings will be published at upcoming scientific conferences. About Sensei Biotherapeutics Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

CollaborateAntibody

100 Deals associated with SNS-01

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-cell lymphoma recurrent	Phase 2	United States	Sevion Therapeutics, Inc.	01 Sep 2011
B-cell lymphoma recurrent	Phase 2	South Africa	Sevion Therapeutics, Inc.	01 Sep 2011
Diffuse large B-cell lymphoma recurrent	Phase 2	United States	Sevion Therapeutics, Inc.	01 Sep 2011
Diffuse large B-cell lymphoma recurrent	Phase 2	South Africa	Sevion Therapeutics, Inc.	01 Sep 2011
Mantle cell lymphoma recurrent	Phase 2	United States	Sevion Therapeutics, Inc.	01 Sep 2011
Mantle cell lymphoma recurrent	Phase 2	South Africa	Sevion Therapeutics, Inc.	01 Sep 2011
Plasma Cell Leukemia	Phase 2	United States	Sevion Therapeutics, Inc.	01 Sep 2011
Plasma Cell Leukemia	Phase 2	South Africa	Sevion Therapeutics, Inc.	01 Sep 2011
Relapse multiple myeloma	Phase 2	United States	Sevion Therapeutics, Inc.	01 Sep 2011
Relapse multiple myeloma	Phase 2	South Africa	Sevion Therapeutics, Inc.	01 Sep 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASGCT2012	Not Applicable	Multiple Myeloma \| Lymphoma	-	SNS01-T	nlftonbxsu(mrjzhtbcat) = gsliykdysu hkizszpflp (txprkheldj, 0.75 mg/kg) View more	-	01 May 2012
				SNS01-T (Control)	nlftonbxsu(mrjzhtbcat) = nztywullcs hkizszpflp (txprkheldj )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SNS-01

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation